Description
Background:
Avdoralimab (IPH 5401) is a fully human IgG monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. It reduces the activation of MDSC and neutrophils in tumor microenvironments, thus exhibiting anti-tumor activity. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research.
Intended Use:
For Estimation of Avdoralimab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Avdoralimab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Avdoralimab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Avdoralimab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Avdoralimab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!